Britt Meelby Jensen

Member of the Novo Holdings Board since 2022. Vice Chair of the Board since 2025.

Britt Meelby Jensen was born in 1973 and is a Danish national. She received a MSc in International Marketing and Management from Copenhagen Business School in Denmark and furthermore received an MBA from Solvay Business School (Université Libre de Bruxelles) in Brussels.

Between 2000-2002, Britt Meelby Jensen worked as a Management Consultant in McKinsey & Company before she joined Novo Nordisk A/S in 2002, where she held several global commercial leadership roles. Hereafter she has held CEO roles at Dako A/S, Zealand Pharma A/S, and at the Swedish MedTech company, Atos Medical AB. In 2022, Britt Meelby Jensen was appointed as CEO of Ambu A/S where she had served as Board member since 2019.

Other Board Positions and Management Duties:

• CEO, Ambu A/S, Denmark

• Board Member, Novo Nordisk A/S, Denmark

• Board member of the Industry Association for Employers in Denmark, IAD, and the Confederation of Danish Industry, DI